Backs FY23 revenue view $1.23B-$1.24B, consensus $1.23B. “We delivered 9.1% constant currency, organic revenue growth in the second quarter of 2023, exceeding the high-end of our expectations,” said Fred Lampropoulos, Merit’s chairman and CEO. “We also delivered significant year-over-year improvements in profitability with non-GAAP gross and operating margins of 51.4% and 19.9%, respectively, and solid year-over-year growth in both non-GAAP net income and non-GAAP earnings per share. We are confident in our team’s ability to deliver our financial guidance for fiscal year 2023 and continued progress in year three of our Foundations for Growth Program and the related financial targets for the three-year period ending December 31, 2023.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MMSI:
- Merit Medical Reports Results For Second Quarter June 30, 2023
- MMSI Earnings this Week: How Will it Perform?
- Merit Medical price target raised to $92 from $85 at Piper Sandler
- Merit Medical Systems to Announce Second Quarter 2023 Results On July 25, 2023
- Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc.